ReviewThe Korean journal of internal medicine2017
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Review in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- CRISPR-Cas12a-based rapid detection of Babesia gibsoni and Ehrlichia canis in dogs using fluorometer platform.Scientific reports · 2025Article
- Addressing the challenges of immunogenicity, heterogeneity and tumorigenicity in the clinical translation of human embryonic stem cells.Stem cell research & therapy · 2025Review
- Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.International journal of molecular sciences · 2024Review
- Extracellular vesicles: Emerging tools as therapeutic agent carriers.Acta pharmaceutica Sinica. B · 2022Review
- An episomal DNA vector platform for the persistent genetic modification of pluripotent stem cells and their differentiated progeny.Stem cell reports · 2022Article
- Ten decadal advances in fungal biology leading towards human well-being.Fungal diversity · 2022Review
- Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment.Frontiers in immunology · 2022Review
- Review
- Identification of Novel Insulin Resistance Related ceRNA Network in T2DM and Its Potential Editing by CRISPR/Cas9.International journal of molecular sciences · 2021Article
- Basic and Preclinical Research for Personalized Medicine.Journal of personalized medicine · 2021Review
- Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer.Biologics : targets & therapy · 2021Review
- Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review).Biomedical reports · 2020Review
- CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.Stem cell research & therapy · 2020Article
- Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.Human genomics · 2020Review
- Applications of RNA interference in the treatment of arthritis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Aging: A cell source limiting factor in tissue engineering.World journal of stem cells · 2019Review
- CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition.PloS one · 2019Article
- Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Review
- CRISPR therapeutic tools for complex genetic disorders and cancer (Review).International journal of oncology · 2018Review
- Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in genome editing with programmable nucleases have opened up new avenues for multiple applications, from basic research to clinical therapy. The ease of use of the technology-and particularly clustered regularly interspaced short palindromic repeats (CRISPR)-will allow us to improve our understanding of genomic variation in disease processes via cellular and animal models. Here, we highlight the progress made in correcting gene mutations in monogenic hereditary disorders and discuss various CRISPR-associated applications, such as cancer research, synthetic biology, and gene therapy using induced pluripotent stem cells. The challenges, ethical issues, and future prospects of CRISPR-based systems for human research are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.